

ECCMID Posters/Presentations Discussed (in order as they appear on podcast)

EPISODE 1: How ECCMID 2019 went viral

1. [ASPECT-NP: a randomized, double-blind, phase III trial comparing efficacy and safety of ceftolozane/tazobactam versus meropenem in patients with ventilated nosocomial pneumonia \(VNP\)](#)
 - a. Paper poster #P1917
 - b. NOTES:

2. [Clinical and microbiologic outcomes by causative pathogen in the ASPECT-NP randomised, controlled, phase III trial evaluating ceftolozane/tazobactam for treatment of ventilator-associated pneumonia](#)
 - a. Mini-oral ePoster #O0302
 - b. NOTES:

3. [Combination antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia: the CAMERA2 randomised controlled trial](#)
 - a. Oral #L0014
 - b. NOTES:

4. [Exebacase \(Lysin CF-301\) improved clinical responder rates in methicillin-resistant Staphylococcus aureus bacteraemia including endocarditis compared to standard of care antibiotics alone in a first-in-patient Phase 2 study](#)
 - a. Oral #L0012
 - b. NOTES:

EPISODE 2: Nerding out at ECCMID 2019

5. [Integration of multi-omics data to unravel antimicrobial resistance mechanisms](#)
 - a. Symposium #S0411
 - b. NOTES:

6. [Taking a pill, a risky gesture? Unexpected effects of non-antibiotic medications on commensal and pathogenic bacteria](#)
 - a. Symposium #S0153
 - b. NOTES:

7. [Phage therapy's coming of age: progress towards the application of bacteriophages in the treatment of infectious diseases](#)
 - a. Symposium #S0896, #S0897, #S0898, #S0899
 - b. NOTES:

8. [Association with 30-day mortality and MIC in patients treated with piperacillin/tazobactam for Escherichia coli and Klebsiella pneumoniae bloodstream infections that are non-susceptible to ceftriaxone from patients enrolled in the MERINO trial](#)
 - a. Paper poster #P2468
 - b. NOTES

EPISODE 3: Tazobactam and Tulips: Hot Topics from ECCMID 2019

9. Beta-Lactam InfusioN Study (BLING III)

- a. NOTES

10. Pro/con: optimised dosing according to PK/PD principles in patients - does it improve the efficacy of antibiotics?

- a. Symposium: #S0486, #S0487
- b. NOTES:

11. Renal impairment increases the risk of thrombocytopenia and anaemia during prolonged treatment with linezolid

- a. Paper poster #P2018
- b. Oral #O1168: Linezolid doses should be lowered in renal impairment to improve safety
- c. Publication: [https://https://www.ncbi.nlm.nih.gov/pubmed/31109977](https://www.ncbi.nlm.nih.gov/pubmed/31109977)
- d. NOTES:

12. Therapeutic drug monitoring (TDM)-guided continuous infusion (CI) of piperacillin/tazobactam (PIP) reduces the mortality of critically ill patients in the intensive care unit (ICU)

- a. Oral #L0007
- b. NOTES:

13. Lack of agreement between fosfomycin susceptibility testing methods against clinical *Pseudomonas aeruginosa* isolates

- a. Paper poster #P1733
- b. NOTES:

14. EUCAST: Redefining susceptibility categories and introducing areas of technical uncertainty

- a. Educational Workshop #W0002
- b. eucast.org/
- c. NOTES:

EPISODE 4: Rapid Fire data from ECCMID 2019

15. Accuracy of T2Candida in invasive candidiasis: a clinical trial

- a. Mini-oral flash #O0046
- b. NOTES:

16. Is the juice worth the squeeze? Rapid identification and antimicrobial susceptibility testing using the Accelerate Pheno TM system

- a. Oral #O0256
- b. NOTES:

17. Evaluation of the FILMARRAY Pneumonia Panel for rapid microbiological diagnosis of pneumonia

- a. Paper poster #P1560
- b. NOTES:

18. How leadership can influence antimicrobial stewardship

- a. Symposium #S0686
- b. NOTES:

19. [Significant change in patients' beliefs and expectations about antibiotic treatment for upper respiratory tract infection as the result of brief educational slideshows delivered immediately prior to general practice consultation](#)
 - a. Oral #00142
 - b. NOTES:

20. [Imipenem-relebactam presentations](#)
 - a. NOTES:

21. [In vitro antibacterial activity of cefiderocol against an international collection of carbapenem-non-susceptible Gram-negative bacteria isolated from respiratory, blood, skin/soft tissue and urinary sources of infection: SIDERO-WT-2014-2016](#)
 - a. Paper poster #P1855
 - b. NOTES:

22. [Characterization of isolates showing high MICs to cefiderocol from global surveillance study SIDERO-CR-2014/2016](#)
 - a. Paper poster #P1857
 - b. NOTES

23. [Cefiderocol susceptibility and geographical analysis against globally isolated meropenem non-susceptible Gram-negative bacteria containing serine- and metallo-carbapenemase gene](#)
 - a. Paper poster #P1853
 - b. NOTES:

24. [Rezafungin \(RZA\) is more effective than micafungin in treating of FKS-mutant Candida glabrata intra-abdominal candidiasis](#)
 - a. Mini-oral ePoster #O0741
 - b. NOTES:

25. [Deletion of Candida auris CDR1 completely restores triazole antifungal susceptibility in a pan-triazole resistant isolate of C. auris](#)
 - a. Mini-oral flash #O0173
 - b. NOTES:

26. [Favourable Response to Oral Ibrexafungerp \(formerly SCY-078\) in Patients with Refractory Fungal Diseases, Interim Analysis by Pathogen from a Phase 3 Open-label Study \(FURI\)](#)
 - a. Oral #L0010
 - b. NOTES:

27. [A double-blind, randomised, placebo-controlled study to evaluate the safety and efficacy of intravenous sulbactam-ETX2514 in the treatment of hospitalised adults with complicated urinary tract infections, including acute pyelonephritis](#)
 - a. Mini-oral ePoster #O0300
 - b. NOTES:

28. [Iclaprim versus vancomycin for patients with acute bacterial skin and skin structure infection complicated by Staphylococcus aureus or streptococcal bacteraemia: a pooled analysis of the phase III REVIVE trials](#)
 - a. Paper poster #P2287
 - b. NOTES:

29. [Oral lefamulin demonstrates favorable safety and tolerability in adults with community-acquired bacterial pneumonia in the phase III lefamulin evaluation against pneumonia \(LEAP 2\) study](#)
 - a. Mini-oral ePoster #O1068
 - b. NOTES:

30. [Phase III dose selection for tebipenem](#)
 - a. Paper poster #P1950
 - b. NOTES:

31. [Activity of tebipenem, an oral carbapenem, against multidrug-resistant urinary tract infection-causing pathogens with characterized resistance mechanisms collected in Europe and the United States in 2016](#)
 - a. Paper poster #P1862
 - b. NOTES: